AF is the most common sustained arrhythmia in clinical practice and is increasing worldwide.
rhythm, respectively). 15 The risk of cognitive impairment was higher in AF patients with other comorbid diseases such as heart failure, diabetes, kidney disease, etc. 16 Worldwide dementia trends show an increased risk in women, particularly in those >80 years of age. Current estimates are that one in two women and one in three men will develop a stroke, dementia or
Parkinson's disease, with the first two diseases comprising the greatest risk. 17 We studied 35,608 patients without a history of AF or dementia.
In this population 14,377 (40.4%) were women. The 5-year rates of AF were higher in men than women (14.0% in men versus 11.9% in women; p<0.0001), although dementia (1.1% in women versus 0.9% in men; p=0.09) and stroke rates (3.4% in women versus 2.6% in men;
p<0.0001) were higher in women. Among the patients who developed AF, the 5-year rate of dementia in women was 2.9% versus 2.3% in men (p=0.180), and the long-term rate was 3.7% in women and 3.0% in men (p=0.110). 18 With these emerging data regarding brain injury, it is critical that we start to expand our view of potential brain injuries in patients with AF ( Figure 1 ).
AF and Dementia Risk with Anticoagulation
If macro-and micro-cerebral ischaemic events are significant mechanisms underlying the association of AF with both vascular and idiopathic forms of dementia, then the initiation, use and efficacy of anticoagulation is critical. We studied this concept in an analysis of 2,605 AF patients with no history of dementia or cognitive impairment.
These patients were enrolled at warfarin therapy start. This analysis showed that as time in therapeutic range (TTR) is decreased among the categories, the associated dementia risk is increased (versus >75%) (<25% HR 5.34; p<0.0001; 26-50% HR 4.10; p<0.0001; and 51-75% HR 2.57; p=0.001). 19 There was a risk of cognitive decline with both over-and under-anticoagulation, suggesting that not only are cerebral ischaemic events a significant risk factor for dementia, but micro-and macro-bleeds also are.
In a more recent national study, 444,106 patients were studied over with no history of dementia, we evaluated the risk of dementia and the potential augmented risk of AF. 25 In both groups there was a higher risk of dementia in patients with a low TTR compared with a high TTR, highlighting the critical role of anticoagulation on outcomes.
Additionally, in a propensity-based analysis the presence of AF conveyed additional risk for general dementia (HR 2.42; p<0.0001) and
Alzheimer's disease (HR 2.04; p<0.0001).
AF and Dementia Risk Related to Arrhythmia, Haemodynamic Changes and Cranial Perfusion
Many patients with AF experience symptoms of fogginess, mental slowing, or feeling off during transitions from sinus rhythm to AF. The correlation of dynamic cognitive changes with arrhythmia transition cannot be explained by a mechanism of repetitive cerebral injury events from macro-or micro-clots or bleeds.
A compelling mechanism to explain abrupt cognitive decline with AF is that the arrhythmia unmasks cerebral microvascular dysfunction. In an autopsy study of Alzheimer's disease patients, cerebral atherosclerosis was common. 26 The most common area of disease was found in the circle of Willis, which is critical to allow adaptive compensation to all brain regions in the setting of altered blood flow or hypotension.
As general vascular risk factors increase, the risk of dementia and the negative relative impact of AF increases. 27 A modelling analysis was performed to examine the haemodynamic impact of AF on brain perfusion. In this analysis, variance in R-R intervals coupled with loss of atrioventricular synchrony result in reduced cranial blood flow that causes repetitive hypoperfusions at The quantitative impact of repetitive microvascular haemodynamic compromise can be significant in AF patients as another cause of chronic ischaemic injuries and, as such, is considered one of the causes of leukoaraiosis or white matter changes. 15 Management of rate and rhythm can improve outcomes. In a small study of patients with persistent AF who were compared with sinus rhythm controls, atrioventricular node ablation resulted in a steady and predictable heart rate (R-R interval), improved frontal and temporal blood flow leading to improved memory and learning and a flow pattern similar to those in sinus rhythm. 29 We have also 
Risk of Dementia Related to Inflammation, Oxidative Stress and Genetic Components in AF
From a histologic evaluation, Alzheimer's disease is associated with the accumulation of abnormally folded beta-amyloid and tau proteins that form cerebral plaques. These plaques are associated with cerebral atrophy and cellular death. Amyloid deposits and misfolded proteins are also seen in degenerative atrial myopathy in AF patients. 31 Whether the same predisposition of atrial changes associated with amyloid deposits is seen in the brain of patients with AF-related cognitive decline is unknown. From a genetic standpoint the apolipoprotein E epsilon4 allele is associated with risk of dementia and amyloid deposits. However, this allele did not act as a second hit or contributor of accelerated cognitive decline in patients with AF. 32 Oxidative stress, inflammation and endothelial dysfunction have been shown to increase the risk of Alzheimer's disease. [33] [34] [35] In patients with AF, biomarkers of oxidative stress, inflammation and endothelial dysfunction are elevated. [36] [37] [38] These markers associated with both disease states suggest both organs that manifest end organ diseasebrain (dementia) and heart (AF) -reflect symptoms of a systemic and inflammatory vascular disease that has early roots in hypertension, obesity, low physical activity and metabolic syndrome. the predictive values of each score are relatively poor, with C-statistics ranging from 0.50-0.70 across multiple cohorts of the study. 40 Although these scores also predict dementia risk, there remains broad variability in risk across all CHADS 2 and CHA 2 DS 2 -VASc strata. 27 Risk scores that can be used dynamically and judge severity of disease will likely perform better, so can potentially have an impact on clinical care. For example, a dynamic score can assist in understanding current brain health and risk when transitioning from warfarin with a low TTR to a DOAC therapy, or after lifestyle modifications including increasing activity, lowering weight and improving blood pressure and glycemic control. Risk factor management is complex and multiple factors related to lifestyle drive both AF incidence, progression and adverse outcomes. 41 When lifestyle modification is advocated in patients -with the assistance of a multidisciplinary team -arrhythmia-related outcomes can be improved, and some diseases can be reversed. This concept has many potential positive inroads towards cognitive health and (low, moderate, high), individually predict risk of incident dementia in both men and women. 42 These scores also segregate risk across all CHA 2 DS 2 -VASc scores highlighting the value of understanding physiology in the setting of baseline risk. 43 The same value of IMRS can be seen in better discerning risk of stroke, as the IMRS improves the C-statistic when combined with CHADS 2 and CHA 2 DS 2 -VASc scores in both men and women. 43 In conclusion, recent guidelines were provided to raise awareness of the critical association between cognitive decline, dementia and cardiovascular disease, to identify key areas of additional research needed and to provide recommendations on how to lower risk. 44 In regard to risk in patients with AF, a recommendation for appropriate anticoagulation was made to prevent stroke and cognitive dysfunction. Other areas that may be useful for recommendations include when to consider a DOAC rather than warfarin, optimising TTR to >70%, managing lifestyle changes such as prevention of smoking, hypertension, obesity, diabetes, sleep apnoea, etc., to lower risk of both disorders, and rhythm control -particularly in younger patients (<65 years of age) -which may include ablation in highly-trained centres with long-term follow-up to optimise post-ablation care.
Clinical Perspective
• AF is associated with long-term risk of cognitive decline and dementia.
• Dementia rates are higher in women and those who have AF.
• Chronic cerebral ischaemic injuries from macro-and microclots and bleeds is a mechanism supported by trials of anticoagulation use and cranial imaging.
• Unmasked cerebral vascular dysfunction, through haemodynamic, oxidative and inflammatory mechanisms, is also a probable mechanism that can explain abrupt cognitive changes with onset of AF.
• Several mechanisms of risk can be targeted with current pharmacological and nonpharmacological therapies that may lower dementia risk and, as such, require prospective study.
